Direct Application of Selective Laser Trabeculoplasty in Open Angle Glaucoma (DSLT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01383525|
Recruitment Status : Recruiting
First Posted : June 28, 2011
Last Update Posted : November 28, 2018
|Condition or disease||Intervention/treatment||Phase|
|Glaucoma||Device: Automated Direct Selective Trabeculoplasty device||Not Applicable|
This is a single site outpatient study assessing the safety & efficacy of the DLTP laser in the ability to reduce IOP in patients with open angle glaucoma (OAG). The investigational site will accrue patients with uncontrolled OAG. These eyes will be treated with the direct application of Direct Laser Trabeculoplasty (DLTP).
Only one eye per patient is to be treated with the investigational device during the study. The laser parameters used will be like these used in the Selective trabeculoplasty (SLT) device (CE/FDA approved), but all laser beams will be applied in about one-second, through the sclera.
Subjects will be evaluated preoperatively and postoperatively at 1 hour, 2 hours (and hourly to 4 hours in the event of an IOP elevation in the immediate postop course), 1 day, 1 week, and 1, 3, 6 months.
Patients will be followed out to 6 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Masking Description:||No masking for treatment. The follow-up and primary endpoint assessment, intra-ocular pressure (IOP) measurement, is performed by masked ophthalmologist.|
|Official Title:||Direct Application of Selective Laser Trabeculoplasty in Open Angle Glaucoma . Single Site Study|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Experimental: Direct Selective Trabeculoplasty
Treatment by an Automated Direct Selective Trabeculoplasty device
Device: Automated Direct Selective Trabeculoplasty device
Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
- Reduction of Intra-Ocular pressure [ Time Frame: 1,3 month ]Percentage reduction of intra-ocular pressure following the non contact selective laser trabeculoplasty treatment
- Reduction of Intra-Ocular pressure [ Time Frame: 6 months ]Percentage reduction of intra-ocular pressure following the non contact selective laser trabeculoplasty treatment
- Number of medications [ Time Frame: 6 months ]Number of medications after treatment, as compared to before treatment.
- Physician perception of the usability of the system. [ Time Frame: 1 month ]Physician perception of the usability of the system.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01383525
|Contact: Mordechai Goldenfeld, MDfirstname.lastname@example.org|
|The Sam Rothberg Glaucoma Center Goldschleger Eye Institute Sheba meical Center||Recruiting|
|Ramat-Gan, Israel, 52621|
|Contact: Mordechai Goldenfeld, MD 972353023046 email@example.com|
|Contact: Michael Belkin, MD 9723-5302956 firstname.lastname@example.org|
|Principal Investigator:||Alon Skaat, MD||Sheba Medical Center|